Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03746535 · ClinicalTrials.gov registry record · Early Phase 1
Cardiovascular Disease Risk in Women With Endometriosis
A Early Phase 1 study of Endometriosis, sponsored by Yale University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03746535 is a Early Phase 1 study of Endometriosis that is actively recruiting participants, run by Yale University. The registered enrollment target is 40 participants, below the 263-participant average among 48 other Endometriosis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03746535, a Early Phase 1 study of Endometriosis, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Conditions Studied
Interventions
- DRUG Elagolix
Study Locations (1)
Connecticut
- Yale School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03746535
The ClinicalTrials.gov registry entry for NCT03746535 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 263-participant average among 48 other Endometriosis trials with a reported enrollment target (85% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 1 intervention - of which Elagolix is the first listed.
NCT03746535 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03746535 about?
NCT03746535 is a clinical study titled "Cardiovascular Disease Risk in Women With Endometriosis". To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
What is the current status of trial NCT03746535?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2022-07-01. Estimated completion is 2026-12-31.
What conditions does trial NCT03746535 study?
This clinical trial studies the following conditions: Endometriosis.
What interventions are being tested in trial NCT03746535?
The interventions under investigation include: Elagolix (DRUG).
Who is sponsoring clinical trial NCT03746535?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03746535 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endometriosis and Microvascular Dysfunction: Role of Inflammation
RECRUITING · Early Phase 1
-
Thromboxane Function in Women With Endometriosis
RECRUITING · Phase 4
-
Interdisciplinary Group Care for the Treatment of Endometriosis-associated Pain
RECRUITING · NA
-
The Impact of Yoga on Endometriosis-Related Pain
RECRUITING · NA
-
Physical Therapy After Endometriosis Excision
RECRUITING · NA
-
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.